Cargando…
Folate Receptor Targeted Alpha-Therapy Using Terbium-149
Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) usi...
| Autores principales: | , , , , , , , , |
|---|---|
| Lenguaje: | eng |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://dx.doi.org/10.3390/ph7030353 http://cds.cern.ch/record/2137140 |